Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus

Bristol-Myers Squibb Co. on Dec. 18 took another step in narrowing its therapeutic focus by selling its pipeline of HIV candidates, including novel Phase III and Phase IIb assets, to ViiV Healthcare in a pair of deals bringing $350m in upfront cash and significant earn-out potential back to the US-based pharma.